Genomic Vision announces the drawing of two new installments for 2 M ?? within the framework of the financing program concluded with Winance for a maximum amount of 12 M ??


Regulatory News:

Genomic Vision (FR0011799907 – GV, eligible for PEA-PME) (Paris: GV), a biotechnology company that develops tools and services dedicated to the analysis and control of genome modifications (the “ Society »), Today announces the issuance of the 5th and 6th tranche of bonds convertible into shares with share subscription warrants (OCABSA) for an amount of 2 million euros.

It is recalled that in the context of a press release dated June 15, 2020, the Company announced the signing of an issue contract on June 11, 2020 with Winance with a view to setting up a line financing by issuance of convertible bonds (the “OC”) into ordinary shares to each of which will be attached a share subscription warrant (the “BSA” and together with the shares to which they are attached the “ABSA” and with the OC the “OCABSA”), for a maximum total amount of 12 million euros. The extraordinary general meeting of shareholders of the Company which met on October 30, 2020 approved the implementation of this financing.

Terms of the transaction

Using the delegation of authority granted to it by the extraordinary general meeting of shareholders, the management board decided to issue 2,000 OCABSAs for a total amount of 2 million euros for the benefit of Winance or any affiliated entity. (the “Investor”).

The CB must be subscribed by the Investor within ten (10) working days following the decision of the management board, if the usual conditions of the request are met.

The gross proceeds of the transaction will therefore be 2 million euros and the net proceeds of 1.9 million euros.

The main characteristics of this financing program, structured in 12 OCABSA tranches for a total amount of € 12 million, are described in the prospectus approved by the Financial Markets Authority (AMF) on February 9, 2021 under number 21-028 and composed of an operations note and a Universal Registration Document approved by the AMF under number R21-002.

***

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company which develops products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in technologies of genome. genome editing and in bioproduction processes. GENOMIC VISION’s proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements necessary for reliable characterization of DNA alterations in the genome. These tools are used in particular for monitoring DNA replication in cancer cells, for the early detection of cancers and for the diagnosis of genetic diseases. Based in Bagneux, in the Paris region, GENOMIC VISION is listed on the regulated market of Euronext in Paris, Compartment C (Euronext: GV – ISIN: FR0011799907).

www.genomicvision.com

Member of indices CAC® Mid & Small and CAC® All-Tradable

WARNING

This press release expressly or implicitly contains forward-looking statements relating to Genomic Vision and its activities. Genomic Vision believes that these forward-looking statements are based on reasonable assumptions. However, no guarantee can be given as to the achievement of the forecasts expressed in these forward-looking statements which are subject to risks, including those described in the “Risk Factors” section of the Universal Registration Document filed with the Autorité des marchés financiers. Marchés Financiers (AMF) on February 9, 2021, under registration number R21-002, which is available on the Company’s website (www.genomicvision.com) and to changes in the economic situation and financial markets and the markets in which Genomic Vision is present. Forward-looking statements contained in this press release are also subject to risks unknown to Genomic Vision or which Genomic Vision does not consider material as of this date. The realization of all or part of these risks could lead to the actual results, financial conditions, performances or achievements of Genomic Vision differ significantly from the results, financial conditions, performances or achievements expressed in these forward-looking statements.

This press release and the information it contains do not constitute, and should not be interpreted as, an offer or invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe to Genomic Vision shares. in any country. The distribution of this press release in certain countries may constitute a violation of the legal provisions in force. Those in possession of the press release should therefore inquire about any local restrictions and comply with them.



Source link -88